| Literature DB >> 34310951 |
Henri Montaudié1, Laura Sormani2, Bérengère Dadone-Montaudié3, Marjorie Heim2, Nathalie Cardot-Leccia4, Meri K Tulic2, Guillaume Beranger2, Anne-Sophie Gay5, Delphine Debayle5, Yann Cheli6, Jérémy H Raymond7, Pierre Sohier7, Valérie Petit7, Stéphane Rocchi2, Franck Gesbert7, Lionel Larue7, Thierry Passeron8.
Abstract
The potential role of CLEC12B, a gene predominantly expressed by skin melanocytes discovered through transcriptomic analysis, in melanoma is unknown. In this study, we show that CLEC12B expression is lower in melanoma and melanoma metastases than in melanocytes and benign melanocytic lesions and that its decrease correlates with poor prognosis. We further show that CLEC12B recruits SHP2 phosphatase through its immunoreceptor tyrosine-based inhibition motif domain, inactivates signal transducer and activator of transcription 1/3/5, increases p53/p21/p27 expression/activity, and modulates melanoma cell proliferation. The growth of human melanoma cells overexpressing CLEC12B in nude mice after subcutaneous injection is significantly decreased compared with that in the vehicle control group and is associated with decreased signal transducer and activator of transcription 3 phosphorylation and increased p53 levels in the tumors. Reducing the level of CLEC12B had the opposite effect. We show that CLEC12B represses the activation of the signal transducer and activator of transcription pathway and negatively regulates the cell cycle, providing a proliferative asset to melanoma cells.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34310951 DOI: 10.1016/j.jid.2021.05.035
Source DB: PubMed Journal: J Invest Dermatol ISSN: 0022-202X Impact factor: 8.551